In 2026, biopharmaceuticals have become a national emerging pillar industry, with the biopharmaceutical industry entering a high-quality development stage. Distilled water machines, the core equipment for WFI preparation, are accelerating iteration towards high energy efficiency, digitalization and full compliance. The new GMP certification is bound with the "dual carbon" goal, promoting technical optimization and solving the pain points of high energy consumption and insufficient compliance of traditional models.
External spiral multi-effect distilled water machines have become the market mainstream. With energy cascade utilization technology, six-effect and above models have a steam consumption of ≤0.18 tons/ton water and thermal efficiency of ≥90%, reducing carbon emissions by over 24 tons/year, in line with green manufacturing needs. Digital transformation has achieved remarkable results; models integrated with digital twins and AI algorithms can real-time monitor water quality and energy consumption, reducing unplanned downtime by 40% with predictive maintenance and improving production continuity.
In terms of compliance, equipment materials and verification systems have been continuously upgraded: medical-grade 316L stainless steel inner tanks are electropolished (Ra≤0.4μm) to eliminate biofilm, complying with ASME BPE and FDA 21 CFR Part 11 standards; full-process IQ/OQ/PQ verification is increasingly improved, adapting to high-end scenarios such as innovative drugs and cell therapy. Data shows that in 2026, the domestic market increased by 14.8% year-on-year, the penetration rate of intelligent and high-energy-efficiency models exceeded 50%, and the export volume of domestic equipment increased by over 15% year-on-year, mainly to countries along the "Belt and Road".
